During the past decade, FGU Russian Scientific Research Institute of Hematology and Transfusiology conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 14 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 6 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "FGU Russian Scientific Research Institute of Hematology and Transfusiology" #1 sponsor was "Celgene" with 5 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Takeda" with 3 trials sponsored, "BeiGene" with 2 trials sponsored and "Celgene Corporation" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "FGU Russian Scientific Research Institute of Hematology and Transfusiology" #1 collaborator was "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "FGU Russian Scientific Research Institute of Hematology and Transfusiology" are "Multiple Myeloma" (4 trials), "Non-Hodgkin's Lymphoma" (2 trials), "Acute Myeloid Leukemia" (1 trials), "B-Cell Chronic Lymphocytic Leukemia" (1 trials) and "B-cell Lymphoma" (1 trials). Many other conditions were trialed in "FGU Russian Scientific Research Institute of Hematology and Transfusiology" in a lesser frequency.

Most popular intervention types in "FGU Russian Scientific Research Institute of Hematology and Transfusiology" are "Drug" (19 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Rituximab" (4 trials), "Azacitidine" (2 trials), "Bendamustine" (2 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.

The vast majority of trials in "FGU Russian Scientific Research Institute of Hematology and Transfusiology" are 19 trials for "All" genders.

Currently, there are NaN active trials in "FGU Russian Scientific Research Institute of Hematology and Transfusiology". undefined are not yet recruiting, undefined are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in FGU Russian Scientific Research Institute of Hematology and Transfusiology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in FGU Russian Scientific Research Institute of Hematology and Transfusiology, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

FGU Russian Scientific Research Institute of Hematology and Transfusiology has several departments that took part in Clinical trials: "Regional Oncology Dispensary" - 2 trials